Last week, Chief Income Strategist Marc Lichtenfeld evaluated the dividend safety of a drug royalty company. Royalty companies often have strong, reliable revenue streams, which can be great news for their dividends. But as Marc shows you in his latest Safety Net, these companies still aren't immune from dividend cuts... |
Post a Comment
Post a Comment